4月18日,GSK公告以20亿美元现金收购$BELLUS Health(BLU)$ ,几乎也只有一款核心品种,是用于治疗难治性慢性咳嗽的P2X3拮抗剂Camlipixant,正在进行临床...查看全文
产业链观察2023-04-18 16:04
#药闻简讯# 重磅!葛$葛兰素史克(GSK)$ 达成协议,收购$BELLUS Health(BLU)$ 每股 14.75美元或20亿美元,溢价约100%。
此次收购使葛兰素史克获得了camlipixant,这是一种潜在的同类最佳和高选择性的P2X3拮抗剂,目前正处于III期开发阶段,用于RCC成年患者的一线治疗。$美国生科ETF-SPDR(XBI)$查看全文
机构木有小G_G2023-04-18 21:42
$BELLUS Health(BLU)$ 美国连续溢价一倍收购创新药公司$博腾股份(SZ300363)$ $凯莱英(SZ002821)$ 药明康德、康龙化成、恒瑞医药
抄送:英维克、剑桥科技、中科曙光、中际旭创、韦尔股份、昆仑万维、中国联通、中国移动、中船特气查看全文
产业链观察2022-05-17 19:42
药闻▶$BELLUS Health(BLU)$ ATS2022上的海报
公布选择性P2x3拮抗剂治疗难治性慢性咳嗽的2b期试验--SOOTHE中24小时客观咳嗽频率的应答者分析。网页链接查看全文
空之客2022-01-24 11:20
既然都知道肿瘤免疫是个修罗场,我们就跳出来关注点儿临床需求明确但现有和潜在治疗手段都比较匮乏的领域,神经相关疾病近些年是国外药企砸了不少钱而国内药企鲜有问津的方向,而其中有不少疾病,无论是流病数据、还是我们日常的体验感受,都知道其实需求十分明确。
上周$默沙东(MRK)$ 用于治...查看全文
BELLUS Health(BLU)2023-06-29 05:05
$BELLUS Health(BLU)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-23-075865 Act: 33 Size: 21 KB 网页链接查看全文
BELLUS Health(BLU)2023-06-29 05:25
$BELLUS Health(BLU)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-23-075894 Act: 33 Size: 21 KB 网页链接查看全文
格隆汇2月24日丨BELLUS Health(BLU.US)涨8.33%,报6.5美元。该公司昨日宣布2b期缓解顽固性慢性咳嗽(RCC)临床试验的结果良好,使BLU-5937成为潜在的同类最佳P2X3拮抗剂。该公司计划在第二季度请求食品和药物管理局(FDA)临床三期前会议,并在2022年下半年启动... 网页链接
$BELLUS Health(BLU)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-23-075891 Act: 33 Size: 21 KB 网页链接
$BELLUS Health(BLU)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-23-075894 Act: 33 Size: 21 KB 网页链接
$BELLUS Health(BLU)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-23-075865 Act: 33 Size: 21 KB 网页链接
$BELLUS Health(BLU)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-23-000434 Act: 34 Size: 2 KB 网页链接
$BELLUS Health(BLU)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001104659-23-075744 Act: 34 Size: 28 KB 网页链接
$BELLUS Health(BLU)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001104659-23-075656 Act: 34 Size: 34 KB 网页链接
$BELLUS Health(BLU)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001104659-23-072257 Act: 34 Size: 38 KB 网页链接
$BELLUS Health(BLU)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001104659-23-068517 Act: 34 Size: 457 KB 网页链接
$BELLUS Health(BLU)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001104659-23-067581 Act: 34 Size: 740 KB 网页链接
$BELLUS Health(BLU)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001104659-23-062771 Act: 34 Size: 5 MB 网页链接